Gurgaon: Medanta– The Medicity, in collaboration with the Association of Radiation Oncologists of India (AROI) hosted the Best of ASTRO India conference. The conference is considered to be the gold standard in the professional education and research in the field of radiation oncology internationally. The conference was attended by the leading Radiation Oncologists from around the world and offered a platform to empower them with latest developments in the field for the benefit of the general public.
Dr. Naresh Trehan, Chairman and Managing Director, Medanta – The Medicity inaugurated the conference and in his address spoke about the role of radiation oncology in cancer treatment. Dr. Trehan said, “It is our endeavor to provide the finest medical care in India, and we therefore strive to propagate the advances in medical care, research and training among the medical fraternity. Treatment of cancer is being made more effective by doctors with super-specialties and advances in equipment, ‘Best of ASTRO’ serves as a platform for knowledge sharing in Radiation Oncology leading to delivery of the best treatment for cancer and also empowering of the patient in defeating cancer.”
Talking about the conference Dr. Tejinder Kataria, Chairperson, Medanta Division of Radiation Oncology and Organizing Secretary of Best of ASTRO India added that “The conference was a great success this year. It provided a great opportunity for those who could not attend ASTRO 2015 to review all the important presentations covering the major sites and take back the frontiers of science to their clinics.”
While launching Tomotherapy in Medanta, Dr. Trehan underlined the relevance of radiation therapy in Cancer treatment. He added, “Radiation Oncology complements surgery and medication in delivering effective cancer treatment and cure. Recognizing that Tomotherapy offers a whole new, revolutionary treatment modality, Medanta has invested significantly and introduced it to India.” Dr. Tejinder Kataria added –“Tomotherapy is the new hope for cancer patients especially leukaemias, lymphomas, carcinoma breast, carcinoma esophagus, prostrate and peadiatric tumors”